NZ702415A - Methods for treating neutropenia using retinoid agonists - Google Patents

Methods for treating neutropenia using retinoid agonists

Info

Publication number
NZ702415A
NZ702415A NZ702415A NZ70241513A NZ702415A NZ 702415 A NZ702415 A NZ 702415A NZ 702415 A NZ702415 A NZ 702415A NZ 70241513 A NZ70241513 A NZ 70241513A NZ 702415 A NZ702415 A NZ 702415A
Authority
NZ
New Zealand
Prior art keywords
methods
treating neutropenia
neutropenia
retinoid agonists
subject
Prior art date
Application number
NZ702415A
Other languages
English (en)
Inventor
Lingtao Wu
Original Assignee
Children’S Hospital Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children’S Hospital Los Angeles filed Critical Children’S Hospital Los Angeles
Publication of NZ702415A publication Critical patent/NZ702415A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NZ702415A 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists NZ702415A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656815P 2012-06-07 2012-06-07
PCT/US2013/044828 WO2013185105A1 (en) 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists

Publications (1)

Publication Number Publication Date
NZ702415A true NZ702415A (en) 2016-04-29

Family

ID=49712715

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ702415A NZ702415A (en) 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists

Country Status (13)

Country Link
US (1) US11116738B2 (enExample)
EP (1) EP2858636B1 (enExample)
JP (1) JP6295249B2 (enExample)
KR (1) KR102083046B1 (enExample)
CN (1) CN104519879B (enExample)
AU (1) AU2013270674B2 (enExample)
BR (1) BR112014030279A2 (enExample)
CA (1) CA2874850A1 (enExample)
ES (1) ES2691493T3 (enExample)
MX (1) MX365321B (enExample)
NZ (1) NZ702415A (enExample)
RU (1) RU2650962C2 (enExample)
WO (1) WO2013185105A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102083046B1 (ko) 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
EP2969031A4 (en) 2013-03-15 2017-03-08 Avisenna Cosmetics LLC Topical compositions for reducing aging effects
PL3277272T3 (pl) * 2015-03-31 2022-01-24 Syros Pharmaceuticals, Inc. Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
TW201823471A (zh) * 2016-10-06 2018-07-01 美商錫羅斯製藥公司 以視黃酸受體-α促效劑及抗CD38抗體治療病患之方法
SG11202006376WA (en) * 2018-01-26 2020-07-29 Agency Science Tech & Res Neutrophil subtypes
CN113969261B (zh) * 2020-07-06 2024-04-09 苏州市立医院(北区) 三步法快速测定中性粒细胞趋化的方法
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
FI131561B1 (en) * 2023-12-28 2025-06-30 Faron Pharmaceuticals Oy CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
EP0957918A1 (en) * 1996-12-19 1999-11-24 American Cyanamid Company Method of treating or inhibiting neutropenia
PT1317537E (pt) 2000-09-08 2007-02-28 Massachusetts Inst Technology Composições e métodos de análogos de g-csf
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
WO2004100972A1 (ja) 2003-05-16 2004-11-25 Kyowa Hakko Kogyo Co., Ltd. 組織破壊を伴う疾患の予防及び／または治療剤
EP1621191A1 (en) * 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
AU2005272653A1 (en) * 2004-08-13 2006-02-23 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
KR20070067189A (ko) 2004-12-02 2007-06-27 비너스 레머디스 리미티드 주사제에 유용한 베타-락타마제 억제제를 이용한베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물
WO2006071451A2 (en) * 2004-12-03 2006-07-06 The Regents Of The University Of California Compounds that prevent macrophage apoptosis and uses thereof
TR201819157T4 (tr) * 2006-05-16 2019-01-21 Io Therapeutics Llc Kemoterapi Ve Veya Radyasyon Terapisinin Yan Etkilerinin Tedavisinde Kullanıma Yönelik Rar Antagonisti Veya Ters Agonisti
NZ580209A (en) * 2007-03-30 2011-11-25 Tmrc Co Ltd Tamibarotene capsule preparation
CN101896200A (zh) * 2007-12-06 2010-11-24 Csl有限公司 抑制白血病干细胞的方法
US8580516B2 (en) 2008-09-05 2013-11-12 University Of Chicago Methods and compositions for direct detection of DNA damage
EP2490543B1 (en) 2009-10-19 2015-07-22 Laila Nutraceuticals Extracts, fractions and compositions comprising acetogenins and their applications
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
US9574179B2 (en) 2011-02-08 2017-02-21 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
US9394315B2 (en) * 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
KR102083046B1 (ko) 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
DE102012011766B3 (de) 2012-06-15 2013-12-19 Voith Patent Gmbh Getriebeeinheit
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
AU2015219038B2 (en) 2014-02-18 2018-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia

Also Published As

Publication number Publication date
EP2858636A1 (en) 2015-04-15
ES2691493T3 (es) 2018-11-27
KR102083046B1 (ko) 2020-02-28
US20150164836A1 (en) 2015-06-18
KR20150035983A (ko) 2015-04-07
AU2013270674A1 (en) 2014-12-18
MX365321B (es) 2019-05-29
EP2858636A4 (en) 2016-06-01
MX2014014930A (es) 2015-07-06
RU2650962C2 (ru) 2018-04-18
JP2015523346A (ja) 2015-08-13
HK1208630A1 (en) 2016-03-11
WO2013185105A1 (en) 2013-12-12
RU2014153988A (ru) 2016-07-27
CA2874850A1 (en) 2013-12-12
US11116738B2 (en) 2021-09-14
CN104519879B (zh) 2018-10-02
EP2858636B1 (en) 2018-09-05
AU2013270674B2 (en) 2017-12-07
JP6295249B2 (ja) 2018-03-14
BR112014030279A2 (pt) 2017-09-12
CN104519879A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
ZA202208792B (en) Methods of treating and preventing graft versus host disease
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2016007965A (es) Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
MX2015006478A (es) Inhibidores de glutaminasa y metodos de empleo.
MX2016012779A (es) Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
MX383893B (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar el cáncer.
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MX352727B (es) Tratamiento de trastorno autoinmune al usar agonistas de rxr.
IL239921A0 (en) Preparations containing solutions in solid state and their use for the treatment of pain
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
NZ704496A (en) Retinoids and use thereof
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
EP3581205A3 (en) Product and method for treating diarrhea
MX2016001104A (es) Composiciones para tratar engrosamiento de la piel.
WO2014146111A3 (en) Analgesic compounds and methods of use
MX394633B (es) Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamina (nmda)
BR112016012248A2 (pt) método de tratamento de nefropatia
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
MX386151B (es) Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple.
MX356102B (es) Compuestos y métodos para tratar leucemia.
MX2012010006A (es) Agonistas de a3ar para el tratamiento de uveitis.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2018 BY COMPUTER PACKAGES INC

Effective date: 20170518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2020 BY COMPUTER PACKAGES INC

Effective date: 20190518

LAPS Patent lapsed